Zepbound for Sleep Apnea: What CPAP Users Need to Know

On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first medication ever authorized to treat obstructive sleep apnea. The approval covers adults with moderate-to-severe OSA and obesity, used alongside diet and exercise.[1] For millions of CPAP users, that headline raised an obvious question: Does this mean I can stop using my machine?

The short answer is NO. Zepbound is not a CPAP replacement. It can reduce the severity of sleep apnea through weight loss, and that's a significant step forward. But CPAP remains the frontline treatment, and your therapy setup will likely need adjusting as your body changes on the medication.

Below, you'll find what the clinical data actually shows, who qualifies, how Zepbound compares to other GLP-1 medications, and what happens to your CPAP equipment as you lose weight. Whether you've just been prescribed Zepbound or you're weighing your options, this breakdown covers the practical side.

What Is Zepbound, and What Did the FDA Just Approve?

Zepbound is Eli Lilly's brand name for tirzepatide, a once-weekly injectable medication. It works as a dual GIP/GLP-1 receptor agonist, meaning it activates two gut hormones that signal to your brain you're full and help your pancreas regulate blood sugar.[2] The result for most patients: you eat less, you lose meaningful weight over months, and as the fat around your neck and upper airway shrinks, your sleep apnea gets less severe.

The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity on December 20, 2024. This makes it the first-ever drug approval specifically for obstructive sleep apnea.[1] Before this, every FDA-approved OSA treatment was a device (CPAP, oral appliances) or a surgical procedure.

Tirzepatide isn't new, though. The same molecule was already approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. The December 2024 approval added OSA to Zepbound's label, giving sleep specialists a pharmacological tool they've never had before.

The primary way Zepbound treats sleep apnea is through weight loss. Excess fat around the upper airway and neck is one of the biggest drivers of airway collapse during sleep. As that fat decreases, the airway stays more open, and breathing interruptions drop.

Does Zepbound Actually Work for Sleep Apnea?

Yes, and the data is strong. In two phase 3 clinical trials called SURMOUNT-OSA, Eli Lilly tested tirzepatide against a placebo in 469 adults with moderate-to-severe sleep apnea and obesity.[3] After 52 weeks, average breathing interruptions per hour (measured by the Apnea-Hypopnea Index, or AHI) dropped significantly in both trials.

Patients who were not using CPAP saw their AHI drop by 25.3 events per hour on tirzepatide, compared to just 5.3 on placebo. Patients already on CPAP saw an even bigger drop: 29.3 events per hour versus 5.5 for placebo.[6]

To put that in perspective, the average baseline AHI in these trials was around 50, which falls in the severe range. A drop of 25-29 events per hour indicates that many participants moved from severe OSA to the mild category or achieved complete remission.

Responder rates were also notable. Between 61% (no CPAP) and 72% (on CPAP) of patients on tirzepatide saw at least a 50% reduction in their AHI. Roughly 4-5 in 10 achieved OSA remission or reached mild apnea with symptom resolution.[3]

Beyond AHI, the trials also tracked secondary outcomes. Systolic blood pressure improved, high-sensitivity C-reactive protein (hsCRP, an inflammation marker) decreased, and hypoxic burden dropped significantly across both studies.

One thing to note: these were Eli Lilly-funded trials. The results are published and peer-reviewed, but long-term real-world data are still being gathered. All participants had obesity and severe OSA, so the findings apply most directly to that population.

What the SURMOUNT-OSA trials found (469 adults, 52 weeks):

Can Zepbound Replace Your CPAP?

No, Zepbound is not a CPAP replacement. Even with the strong AHI reductions in the SURMOUNT-OSA trials, many patients ended the year still inside the apnea range. CPAP works starting on night one by mechanically holding your airway open. Zepbound works over months by reducing the fat that closes the airway in the first place.

The trials showed that CPAP plus tirzepatide produced larger reductions in AHI than tirzepatide alone (29.3 versus 25.3 events per hour). The two treatments complement each other, and the best outcomes were achieved by using both.[3]

About 42% to 50% of patients reached remission or mild OSA with symptom resolution. That's encouraging, but it also means roughly half of patients still had clinically significant sleep apnea after a full year on the medication.

The hard rule: never stop CPAP on your own. A follow-up sleep study with your specialist is the only way to confirm whether your OSA has improved enough to adjust or discontinue CPAP. Plan for re-testing every 6 to 12 months while you're on Zepbound.

For a deeper look at how weight loss affects OSA severity, our guide to weight loss and sleep apnea covers the research in detail.

Who Is Eligible for Zepbound for Sleep Apnea?

Zepbound is approved for adults who have both moderate-to-severe obstructive sleep apnea and obesity (BMI of 30 or above), used alongside a reduced-calorie diet and increased physical activity.[1] You'll need a confirmed diagnosis from a sleep study before a doctor can prescribe it for OSA.

The FDA label carries a boxed warning for thyroid C-cell tumors. Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other groups who may not be eligible include children, women who are pregnant or planning a pregnancy, people with a history of pancreatitis (discuss with your doctor), and those with severe gastrointestinal disease.

Insurance and cost

Coverage varies widely. Prior authorization is the norm for Zepbound, and most insurers require documentation of a confirmed OSA diagnosis and BMI. Medicare Part D coverage is improving but remains plan-dependent. Eli Lilly offers a Zepbound Savings Card that can lower monthly costs for eligible commercially insured patients. Without coverage, retail pricing runs in the high hundreds per month.

To check your coverage, call your insurer's pharmacy benefits line. Ask whether Zepbound (tirzepatide) is on the formulary for OSA, what prior authorization documentation is needed, and whether the Lilly Savings Card applies to your plan.

Haven't had a sleep study yet? A home sleep test can confirm your diagnosis, which is required before Zepbound can be prescribed for OSA. And if you're unsure whether you have symptoms, you might be surprised to learn that sleep apnea doesn't always involve snoring.

What About Other GLP-1s (Wegovy, Ozempic, Mounjaro, Trulicity, Saxenda)?

Only Zepbound (tirzepatide) is FDA-approved for sleep apnea. Other GLP-1 medications are approved for weight loss or type 2 diabetes, and any improvement in sleep apnea they provide is indirect, through weight loss itself.

A common point of confusion: Mounjaro and Zepbound contain the same active ingredient (tirzepatide), but they have different FDA labels. Mounjaro is approved for type 2 diabetes. Zepbound carries the weight management and OSA labels. Your doctor prescribes one or the other based on your condition.

Smaller studies on liraglutide (the active ingredient in Saxenda and Victoza) showed modest improvements in AHI, but none of these medications have a formal FDA indication for OSA.[5]

GLP-1 medications and which ones are FDA-approved for what:

How Your CPAP Therapy Changes When You Lose Weight on Zepbound

This is the part of the Zepbound conversation that most articles skip: what happens to your CPAP gear as you lose weight. Three things tend to shift, and each one has a clear solution.

1. Your prescribed pressure may need to drop

Less fat around your airway means less pressure is needed to keep it open. If you're on a fixed-pressure CPAP, your old setting may start to feel too aggressive. Common signs include bloating, aerophagia (swallowing air), dry mouth, and increased leak warnings. The fix is either a clinical re-titration with your sleep specialist or switching to an auto-adjusting machine (APAP), such as the ResMed AirSense 11 AutoSet, which automatically adjusts pressure as your breathing changes overnight.

2. Your mask may stop sealing properly

As your face and neck circumference decrease with weight loss, the mask cushion that fit perfectly before may start leaking. You might hear hissing air, get a dry mouth from a leak, or see leak warnings in your machine's app. The solution is a refit. Our full-face masks collection includes smaller cushion sizes that work well for patients whose facial contours have changed.

3. You may want a travel CPAP

More energy and more weight loss often mean more travel and more activity. A full-size home CPAP isn't always practical on the go. The ResMed AirMini AutoSet weighs about 11 ounces and delivers the same auto-adjusting therapy in a fraction of the size. It's the most popular travel CPAP among Sleeplay customers for exactly this reason.

The hard rule stays the same: never adjust your prescribed pressure without your sleep specialist. Plan for re-titration every 6 to 12 months while you're on Zepbound, and schedule a follow-up home sleep test to track how your AHI is changing.

What changes for your CPAP gear during Zepbound weight loss:

Gabriel (Sleeplay CPAP Specialist): "The FDA recently approved a GLP-1 medication, a drug originally developed for diabetes and weight loss, as a treatment for sleep apnea in people with obesity. Less fat in the airway means fewer blockages and better, more restful sleep."

Dosing, Side Effects, and Things to Watch For

Zepbound is a once-weekly subcutaneous injection. You inject it under the skin of your abdomen, thigh, or upper arm. Your doctor starts you at 2.5 mg per week and gradually steps the dose up over months, progressing through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg per week.[2]

The slow escalation gives your body time to adjust and reduces the gastrointestinal side effects that are most common in the first weeks at each new dose level. Specifically for sleep apnea, the SURMOUNT-OSA trials used weekly doses of 10 mg or 15 mg.[3]

Most common side effects

GI symptoms top the list: nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate and tend to fade after the first few weeks at each dose step-up. Staying hydrated, eating smaller meals, and following your doctor's escalation schedule all help.

Less common but serious

Pancreatitis (rare), gallbladder issues, kidney effects from severe dehydration, and allergic reactions have been reported. The boxed warning about thyroid C-cell tumors (based on rodent studies) means Zepbound is contraindicated for anyone with a personal or family history of MTC or MEN 2. If you experience severe abdominal pain, contact your doctor right away.

Zepbound dose escalation typical schedule:

For additional lifestyle strategies that support your sleep apnea treatment alongside medication, our sleep apnea lifestyle changes guide covers the daily habits that make the biggest difference.

What to Do Right Now (Your Situation)

Zepbound is genuine progress in treating sleep apnea, and the data supporting its approval are unusually strong. It's also not a magic substitute for CPAP. The cleanest way to use this news is to keep CPAP as your foundation, schedule a re-titration with your sleep specialist every 6 to 12 months on Zepbound, and let your equipment evolve with your body. Sleeplay offers auto-adjusting CPAP machines, smaller-fit masks, and travel CPAPs that make the journey easier.

What to do this week, depending on your current situation:

 

FAQs

Is Zepbound FDA-approved for sleep apnea?

Yes. The FDA approved Zepbound (tirzepatide) on December 20, 2024, as the first medication ever authorized to treat obstructive sleep apnea. The approval is specifically for moderate-to-severe OSA in adults with obesity, used alongside a reduced-calorie diet and increased physical activity. It contains the same active ingredient as Mounjaro.

Can Zepbound replace my CPAP?

No. Even patients who saw strong AHI reductions in clinical trials usually ended the year with some residual sleep apnea. CPAP works the first night and every night; Zepbound works gradually through weight loss. After sustained weight loss, some patients are cleared to stop CPAP, but only after a follow-up sleep study confirms it. Never stop CPAP without your sleep specialist's approval.

How much does Zepbound reduce sleep apnea in the trials?

After 52 weeks of weekly tirzepatide, the average AHI dropped by 25 events per hour in patients not on CPAP and by 29 events per hour in patients already on CPAP. About 61 to 72 percent of participants saw at least a 50% reduction in AHI, and about 42 to 50 percent achieved OSA remission or mild OSA with symptom resolution.

What about other GLP-1 drugs like Wegovy, Ozempic, or Trulicity?

Only Zepbound is FDA-approved specifically for sleep apnea. Wegovy and Ozempic, both semaglutide, and Trulicity (dulaglutide) are approved for weight loss or type 2 diabetes, not for OSA. Smaller studies on liraglutide showed modest improvements in AHI, but no formal FDA sleep apnea indication exists for any GLP-1 drug other than tirzepatide.

What happens to my CPAP pressure if I lose weight on Zepbound?

Your CPAP pressure usually needs to come down as you lose weight, because less fat around your airway means less pressure is needed to keep it open. If you stay on a fixed-pressure machine, your old setting may feel too high, causing bloating, dry mouth, or leak warnings. The two options are a clinical re-titration with your sleep specialist every 6 to 12 months, or switching to an auto-adjusting APAP machine that automatically adjusts pressure nightly.

References

1. U.S. FDA. "FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024."

2. Eli Lilly and Company. "Zepbound (tirzepatide) official product page."

3. Malhotra A, Grunstein RR, Fietze I, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM 2024 (SURMOUNT-OSA). NCT05412004. PMID 38912654."

4. Eli Lilly Investor News. "FDA approves Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity. December 2024.

5. American Academy of Sleep Medicine. "What clinicians should know about prescribing tirzepatide for sleep apnea."

6. Eli Lilly Medical Affairs. "What was the effect of Zepbound on people with moderate to severe sleep apnea and obesity?"